Juqian Zhang

Dr. Juqian Zhang

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BBBen Buckley
Ben Buckley
DLDeirdre Lane
Deirdre Lane
PCPeter Calvert
Peter Calvert
JZJuqian Zhang
Juqian Zhang
DGDavid Gent
David Gent
Gregory LipGregory Lip
Gregory Lip
Background: There is a plethora of real-world data on the safety and effectiveness of direct-acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to inconsistent findings. We compared the effectiveness and safety of apixaban with those of other direct-acting oral anticoagulants (DOACs) and vitamin K antagonists (VKA e.g., warfarin). Methods: A systematic review and meta-analysis was conducted retrieving data from PubMed, SCOPUS and Web of Science from January 2009 to December 2021. Studies that evaluated apixaban (intervention) prescribed for adults (aged 18 years or older) with AF for stroke prevention compared to other DOACs or VKAs were identified. Primary outcomes included stroke/systemic embolism (SE), all-cause mortality, and major bleeding. Secondary outcomes were intracranial haemorrhage (ICH) and ischaemic stroke. Randomised controlled trials and non-randomised trials were considered for inclusion. Results: In total, 67 studies were included, and 38 studies were meta-analysed. Participants taking apixaban had significantly lower stroke/SE compared to patients taking VKAs (relative risk (RR) 0.77, 95% confidence interval (CI) 0.64–0.93, I2 = 94%) and dabigatran (RR 0.84, 95% CI 0.74–0.95, I2 = 66%), but not to patients administered rivaroxaban. There was no statistical difference in mortality between apixaban and VKAs or apixaban and dabigatran. Compared to patients administered rivaroxaban, participants taking apixaban had lower mortality rates (RR 0.83, 95% CI 0.71–0.96, I2 = 96%). Apixaban was associated with a significantly lower risk of major bleeding compared to VKAs (RR 0.58, 95% CI 0.52–0.65, I2 = 90%), dabigatran (RR 0.79, 95% CI 0.70–0.88, I2 = 78%) and rivaroxaban (RR 0.61, 95% CI 0.53–0.70, I2 = 87%). Conclusions: Apixaban was associated with a better overall safety and effectiveness profile compared to VKAs and other DOACs.

1 November 2022 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
Gregory LipGregory Lip
Gregory Lip
YGYing Gue
Ying Gue
JZJuqian Zhang
Juqian Zhang
TCTze-Fan Chao
Tze-Fan Chao
HCHugh Calkins
Hugh Calkins
TPTatjana Potpara
Tatjana Potpara

28 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JZJuqian Zhang
Juqian Zhang
Arnaud BissonArnaud Bisson
Arnaud Bisson
GFGrégoire Fauchier
Grégoire Fauchier
ABAlexandre BODIN
Alexandre BODIN
JHJulien Herbert
Julien Herbert
LFLaurent Fauchier
Laurent Fauchier
Background: Hyperthyroidism is associated with atrial fibrillation (AF), and the latter is a major risk factor for stroke. Aim: We aimed to investigate the yearly incidence of stroke and bleeding in AF patients with and without concomitant hyperthyroidism from the French National Hospital Discharge Database. Methods: Admissions with AF between January 2010 and December 2019 were retrospectively identified and retrieved from the French national database. Incidence rates of ischaemic stroke and bleeding were compared in AF patients with and without concomitant hyperthyroidism. The associations of risk factors with ischaemic stroke were assessed by Cox regression. Results: Overall 2,421,087 AF patients, among whom 32,400 had concomitant hyperthyroidism were included in the study. During the follow-up (mean: 2.0 years, standard deviation SD: 2.2 years), the yearly incidence of ischaemic stroke was noted to be 2.6 (95% confidence interval CI: 2.5–2.8) in AF patients with concomitant hyperthyroidism, and 2.3 (95%CI: 2.3–2.4) in non-thyroid AF patients. Hyperthyroidism was noted as an independent risk factor for ischaemic stroke (adjusted hazard ratio aHR: 1.133, 95%CI: 1.080–1.189) overall, particularly within the first year of hyperthyroidism diagnosis (aHR 1.203, 95%CI 1.120–1.291), however, the association became non-significant in subsequent years (aHR 1.047, 95%CI 0.980–1.118). Major bleeding incidence was lower in the hyperthyroid AF group in comparison to the non-thyroid AF group (incidence ratio: 5.1 vs. 5.4%/year, p < 0.001). The predictive value of CHA2DS2VASc and HAS-BLED scores for ischaemic stroke and bleeding events, respectively, did not differ significantly between AF patients with or without concomitant hyperthyroidism. Conclusions: Hyperthyroidism seems to be an independent risk factor of ischaemic stroke in AF patients, particularly within the first year of hyperthyroidism diagnosis.

3 September 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JZJuqian Zhang
Juqian Zhang
SVS R Vallabhaneni
S R Vallabhaneni
Gregory LipGregory Lip
Gregory Lip
This editorial refers to ‘Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial’, by M.J. Krantz et al., https://doi.org/10.1093/eurheartj/ehab408.

2 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JZJuqian Zhang
Juqian Zhang
Arnaud BissonArnaud Bisson
Arnaud Bisson
JBJAD BOUMHIDI
JAD BOUMHIDI
JHJulien Herbert
Julien Herbert
CEChristophe Saint Etienne
Christophe Saint Etienne
LFLaurent Fauchier
Laurent Fauchier
Mitral regurgitation (MR) is the most common valvular lesion in transcatheter aortic valve implantation (TAVI) recipients. This study aims to assess the long-term prognostic impact of baseline MR in TAVI patients. Methods: Adult patients who underwent TAVI were identified in the French National Hospital Discharge Database. All-cause and cardiovascular mortality, stroke, and rehospitalization with heart failure (HF) were compared in TAVI patients with and without baseline MR and tricuspid regurgitation (TR), respectively; the associations of MR and TR with the outcomes were assessed by Cox regression. Results: Baseline MR was identified in 8240 TAVI patients. Patients with baseline MR have higher yearly incidence of all-cause mortality (HR: 1.192, 95% confidence interval CI: 1.125–1.263), cardiovascular mortality (HR: 1.313, 95%CI: 1.210–1.425), and rehospitalization for heart failure (HF) (HR: 1.411, 95%CI: 1.340–1.486) compared to those without, except for stroke rate (HR: 0.988, 95%CI: 0.868–1.124). Neither baseline MR nor TR was an independent risk predictor for all-cause mortality or cardiovascular mortality in TAVI patients. Baseline MR was independently associated with rehospitalization for HF in TAVI patients. Conclusions: Baseline MR and TR were associated with increased all-cause and cardiovascular mortality post-TAVI, however, neither of them was independent predictor for all-cause or cardiovascular mortality.

24 August 2021 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
JZJuqian Zhang
Juqian Zhang
CZCan Zhou
Can Zhou
MIMahnoor Ihsan
Mahnoor Ihsan
ATAndreas Tsangarides
Andreas Tsangarides
SASarah Ahmed
Sarah Ahmed
RSRajiv Sankaranarayanan
Rajiv Sankaranarayanan
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of intravenous continuous infusion versus bolus injection of loop diuretics for the initial treatment of acute decompensated heart failure.